This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk06: Welcome again to RIAM's second quarter 2024 earnings conference call and webcast. Joining me on today's call are Delisle Blomquist, our president and chief executive officer, and Marcus Bultner, our chief financial officer and senior vice president of finance. Our earnings release and presentation materials were issued last evening and are available on our website, RIAM.com. I'd like to remind you that in today's presentation, we will include forward-looking statements made pursuant to the safe harbor provisions of federal securities laws. Our earnings release, as well as our filings with the SEC, list some of the factors which may cause actual results to differ materially from the forward-looking statements we may make. They are also referenced on slide two of our presentation materials. Today's presentation will also reference certain non-GAAP financial measures, as noted on slide three of our presentation. We believe non-GAAP financial measures provide useful information for management and investors, but non-GAAP measures should not be considered an alternative to GAAP measures. A reconciliation of these measures to their most directly comparable GAAP financial measures are included on slides 20 through 25 of our presentation materials. And now I'll turn the call over to Delisle.
spk10: Thank you, Mickey, and good morning. I'll start with a financial overview for the second quarter of 2024. After that, I'll outline recent company actions before handing over to Marcus, who will provide more details on the business segments, capital structure, and liquidity. Following Marcus's remarks, I'll return to discuss our ongoing initiatives and updated guidance for 2024. This will include updates on the progress towards suspending operations at our Temiscamingh HBC plant and brief comments on the sales process of our paperboard and high yield pulp businesses. We will then open the floor for questions. Let's turn our attention to slide four, where we'll discuss our strong second quarter performance. Adjusted EBITDA reached $68 million, a $41 million or 152% increase from the same quarter last year. In the high-purity cellulose segment, EBITDA improved by $38 million or 136%, driven by higher sales volumes for cellulose specialties, decreased costs for key inputs and logistics, and improved productivity. Additionally, this quarter's results included a $5 million benefit from a Canadian wage subsidy received during the COVID pandemic, but was recognized during this quarter due to the completion of the government audit of the benefit. The paperboard segment experienced a $5 million or 50% increase in EBITDA, driven by higher sales volumes, lower costs for purchased pulp, and a $2 million benefit from the Canadian wage subsidy. These gains were partially offset by lower sales prices. In the high-yield pulp segment, EBITDA rose by $1 million, primarily due to reduced logistics and chemical costs, along with a $2 million benefit from the Canadian wage subsidy. However, these improvements were largely offset by lower sales prices and volumes. Corporate expenses increased by $3 million, driven by higher costs related to the ERP projects variable compensation, and discounting and financing fees to support our working capital initiatives. These were partially offset by our favorable foreign exchange impact. In summary, the overall performance was driven by strong results in our core cellular specialty segment as we continued to pivot our mix to more specialty production and sales and focused cost reduction across the enterprise, which more than compensated for softness in some of our commodity businesses. Last quarter, we announced a significant transaction to monetize our lumber duty refund rights for $39 million. I'm happy to report that we finalized that transaction in June and have received $39 million as expected. This was reflected in our strong year-to-date pre-cash flow generation of $69 million. The process to indefinitely suspend operations at our Temiscaming HBC plant remains on track. Under current market conditions, the suspension is yielding positive EBITDA benefits and enhanced our consolidated free cash flows. Considering these updates and our strong performance in the first half of the year, I am pleased to increase our full-year EBITDA guidance to $205 to $215 million and to raise our full-year adjusted free cash flow guidance to $100 to $110 million. With that, I'll hand it over to Marcus to walk us through the financials for the quarter.
spk03: Marcus. Thank you, Delisle. Beginning with our HPC segment on slide five, quarterly sales increased by $32 million, or 11% to $332 million. Overall, HPC pricing increased 5%, reflective of a higher mix of CS products, whereas total sales volumes increased by 5%. resulting from a 25% increase in CS sales, partially offset by a 13% decrease in commodity sales. EBITDA margins in the HPC segment reached 20%, demonstrating the success of our initiatives to enhance product mix and prioritize specialties. The rise in CS sales volumes was supported by the closure of a competitor's plant in late 2023, the continued muted recovery in ether sales, and bridge volumes from the indefinite suspension of the Tomiskaming HPC plant. Other sales for the corridor were $23 million, which included $13 million of green energy sales. EBITDA for the HPC segment rose by $38 million to $66 million, primarily due to an enriched mix of CS sales previously noted and the benefit of decreased costs for key inputs and logistics, along with the impact of improved productivity. This quarter's results also included $5 million for the SEWS benefit. Turning to slide six, sales in the paperboard segment increased by $12 million, driven by higher sales volumes. EBITDA for the segment improved by $5 million, reaching $15 million, primarily as a result of increased sales volumes and the benefit of decreased purchase pulp costs. In addition, the segment included 2 million for sous. Turning to the high-yield pulp segment on slide 7, sales declined by 11 million in comparison to the prior year, reflecting a 25% drop in sales volumes and a 9% decline in sales prices due to overall reduced demand and the impact of market supply dynamics in China. Segment EBITDA improved $1 million to $2 million as compared to the prior year quarter. The quarter's results also included a $2 million benefit for SEWS. Transitioning to slide 8, consolidated operating income for the quarter amounted to $28 million, reflective of a $35 million improvement versus the second quarter of last year. This positive change was primarily driven by improved product mix favoring HPC CS grades, which more than compensated for lower sales prices. The increased sales volumes in CS and paper board were partially offset by reduced sales for commodity HPC products and high-yield pulp. Other cost benefits, including the impact of favorable foreign exchange rates and a $10 million SUSE benefit contributed to improved results. These positive gains were partially offset by higher costs to support the company's ERP project, increased variable compensation, as well as discounting and financing fees incurred to support working capital initiatives. Now let's turn to slide 9. Gross debt ended the quarter at $795 million, a reduction of $44 million from the same period in 2023. Net secured debt, as reflected in our financial covenant ratio associated with the term loan, ended the quarter at $659 million. Net secured leverage reduced further and closed the quarter at 3.4 times, well within the covenant test. Liquidity remains strong at $260 million, reflecting $114 million of cash, $135 million available under our ABL facility and 11 million from our French factoring facility. Year-to-date capex totaled 58 million, with 28 million allocated towards strategic capital to support the startup of the Tartas bioethanol project and the implementation of our upgraded ERP system. Net of financing, strategic capital reached 17 million. Currently, all planned major maintenance outages for 2024 have now been completed. And additionally, as Delisle mentioned, we successfully completed the sale of our duty refund rates for 39 million. Overall, our liquidity remains strong, positioning us well to achieve our targeted $70 million debt reduction this year. We are actively pursuing the refinancing of our senior notes before going current in January of 2025 and expect the company's improving business performance and enhanced credit metrics will enable the company to complete the refinancing by year end. With that, I'd like to turn the call back over to Dilal.
spk10: Thank you, Marcus. Let's now turn our attention to slide 10, where I'll provide an update on our key initiatives for 2024. Our top goal this year is to refinance the 2026 Senior Notes before they go current in January 2025. working closely with our advisors at Houlihan Loki, who are actively exploring refinancing options and engaging with the market to secure the best terms. In support of this refinancing effort, we are also on track to achieve our target of reducing gross debt by $70 million in 2024, supported by business-generated free cash flow, a tax refund, and proceeds from the recent sale of the duty refund rights. We enjoy strong interest among potential lenders. Therefore, we are confident in completing the refinancing at satisfactory terms within the year. The sales process of our paperboard and high-yield pulp assets is progressing. We have received offers for the domestic domain assets from multiple parties, but these parties have not met our criteria to transact a sale. We are continuing a dialogue with various parties and expect to continue diligence as we work through the complexities of the suspension of the HBC operations at Tumiskamee. We are committed to completing a sale of these assets if we receive an appropriate offer, which values the high EBITDA margins and the low custodial capital intensity of the combined paper board and high-yield businesses. While the proceeds from the sales would significantly reduce our debt load, we are carefully balancing the estimated annual $50 million in free cash flow from these businesses against any potential debt repayment. Given the length of the process, we expect to refinance the 2026 senior secured notes at satisfactory terms prior to a potential sale of these assets. In April, we announced our decision to indefinitely suspend the operations of our Temiscaming HBC plan. This decision in part reflected our commitment to mitigating the financial drag from non-FLUF commodities, which we projected at the time would result in a 2024 EBITDA loss of $48 million. As a result of the suspension, we forecast these non-slough commodity losses to be reduced by nearly half this year, while also improving the supply-demand balance in the core cellulose specialty market. The suspension continues per plan, with operations suspended on July 16, 2024, slightly later than announced to utilize all the raw materials. Mothball activities have commenced and will continue through October. The customer qualification process is ongoing, and we expect to retain approximately half of the CS sales volume and a significantly higher percentage of the EBITDA that was historically sourced from Temiscaming. Going forward, these CS products will be produced from our A&B lines at Jessup and our sulfite plants at Fernandina and Tardis. We remain committed to our fluff business with most of the C-line adjusted and continuing to focus on fluff production. We have upgraded our forecasted financial impact of the suspension for 2024 to a $10 to $15 million positive impact on adjusted EBITDA and a $25 to $30 million positive impact on free cash flow. We estimate one-time cost of $25 to $30 million for severance, benefit extensions, outplacement services, and mothballing. The recurring financial impact remains as announced, with an adjusted EBITDA improvement of $15 to $20 million after customer qualifications are completed, primarily due to reduced EBITDA losses from commodity sales. Free cash flow is expected to increase by $30 to $35 million due to the adjusted EBITDA improvement and avoid a custodial capex for the Temiscaming HBC plan. As previously stated, We will routinely monitor the status of this indefinite suspension in light of economic conditions, market dynamics, and other relevant factors. One of our most promising initiatives involves our biomaterials business. We are nearing completion of the detailed engineering phase for our Fernadina bioethanol plant. The project's permitting timeline has been extended by public participation. which is not uncommon and is being addressed through the regulatory process. This could result in a delay of the construction timeline of this project. We have submitted a notice for grass self-certification for our prebiotics animal feed product and expect to begin production trials in September. We are advancing other projects in our biomaterials project pipeline, including the proposed AGE project at our Jessup facility which will produce green energy for sale, and crude tall oil operations in both France and the U.S. We aim to primarily finance these projects with green capital. Let's turn to slide 11. We are updating our guidance and now expect to achieve adjusted EBITDA of $205 to $215 million for the year. The first half results exceeded expectations as we benefited from the recognition of $10 million in benefits related to SEWS. We also benefited from customers advancing CS orders ahead of the indefinite suspension of our operations at the Tamiskameen HBC plant. While we don't expect the advancing order to repeat in the back half of 2024, we do expect to retain a majority of these sales in the future as we re-qualify production at our other plants. Overall, we still expect solid results in the back half of 2024 driven by increased specialty sales and reduced operating costs. Cash interest expense is projected at approximately $85 million, which includes a $15 million payment made in early January for last year's Q4 due to the timing of the interest payment around the holidays. Maintenance capex is now estimated at $75 million, reflecting a $10 million reduction due to the suspension. of the Temiscaming HPC plant. Additionally, we project a $35 million benefit from working capital, which includes $25 million resulting from the Temiscaming HPC plant suspension. Furthermore, we anticipate $15 million in tax refunds and have successfully completed the transaction for $39 million for the monetization of the lumber duties. These gains will be partially offset by impacts related to the TBHPC plant suspension and other accrued liabilities. In sum, we are raising our adjusted free cash flow guidance to a range of $100 to $110 million for the year. These funds will be allocated toward debt reduction and strategic capital investments. On slide 12, I dive deeper into the expected 2024 performance of each of our businesses. We project EBITDA for HPC segment to be in the range of $205 to $215 million. We anticipate cellulose specialty prices to increase by a low single-digit percentage compared to 2023 as we continue to prioritize value over volume. Sales volumes for cellulose specialties are expected to increase due to a competitor's plant closure, an uptick in ether sales, and bridge volumes from the temiscamine HPC suspension. These gains will be partially offset by acetate to stocking and changes in prior-year contract terms. Demand for commodity HPC products remains stable with prices flat compared to 2023, and we project a slight increase in H2 2024 sales volumes driven by increased fluff sales. We expect overall costs to be lower in 2024 due to reduced input and logistics costs, improved productivity, and the temiscamine HPC suspension, partially offset by net stranded costs related to the suspension. We anticipate Q3 2024 EBITDA to be significantly stronger than Q3 2023. However, it will be lower than Q2 2024 due to the end of the CEWS benefit and CS bridge volumes, as well as increased stranded costs from the temiscamine suspension
spk02: of the HBC plant.
spk10: Our growth strategy is centered on strategic investments in our biomaterials business. We have outlined several promising projects and have strong confidence in the earnings potential of both our current and upcoming initiatives. Our first project, the Tardis Bioethanol Plant, is already generating positive earnings and is expected to contribute $3 to $4 million to EBITDA this year. growing to $8 to $10 million in 2025 as we achieve targeted production levels. With the addition of the remaining projects in Portfolio 1, we anticipate achieving $40 million plus of EBITDA from these initiatives on $100 million of revenue in 2027. Regarding paper boards, we expect to achieve EBITDA of approximately $50 million in 2024. Prices are expected to decrease slightly in the second half of 2024, while sales volumes are projected to increase slightly as inventories reduce, despite higher planned maintenance downtime for a distributive control system upgrade. However, raw material prices are expected to rise due to increased purchase pulp costs. Consequently, we anticipate EBITDA to decline in the coming quarter. We expect our high-yield pulp business to achieve EBITDA of approximately $5 million in 2024. Second half 2024 prices are expected to decline due to pricing pressures from stranded pulp capacity in China. However, sales volumes are projected to increase due to improved productivity. As a result, we expect EBITDA to be moderately higher in the coming quarter. For 2024, we expect corporate costs of $55 million in line with 2023 as we are in the final year of our multi-year ERP project implementation. Corporate costs are expected to increase slightly in the second half of 2024 due to this project and less favorable foreign exchange rates. As the ERP project concludes, we anticipate system enhancements and cost reductions starting in 2025. It's important to note that these costs may vary due to factors like currency fluctuations, environmental charges, and other non-cash expenses. Turning to slide 13, we want to provide an update on the current supply-demand dynamics in our core cellular specialties market. Given the recent capacity reductions with the GP Foley facility and the indefinite suspension of our Temiscaming HPC facility, We have seen an approximate 10% to 12% reduction in industry capacity. We believe the current market dynamics indicate a tight supply-demand balance. Industry analysts project a supply-demand ratio to be around 87% in 2024, growing to 92% in 2026. Inclusive of deep bottlenecking capacity increases from the remaining market participants. We view anything above 87%. as a supply-constrained market. With this favorable market outlook, we turn to slide 14, where we illustrate the trajectory of our EBITDA margin growth and net leverage decline. In 2024, we anticipate our margins to be in the 12% range. The forecast for net secured leverage at the end of the year stands at 2.8 times Covenant EBITDA. We are confident that we will achieve our target Our target net debt leverage ratio of 2.5 times well before 2027. With that, operator, please open the call to questions.
spk00: At this time, I would like to remind everyone in order to ask a question, press star, then the number one on your telephone keypad. Again, a star followed by the number one on your telephone keypad. Your first question comes from the line of Matthew McCullough with RBC Capital Markets. Matthew, your line is now open.
spk04: Hi, good morning. Thanks for taking my questions. Maybe first, just on your sale process for the high-yield pulp and paper board business, I think you mentioned that parties have submitted bids, but they have not met your criteria. Is this a comment on price alone, or is there anything else worth considering here? And then, are you able to give us a sense of how far apart the offers are that you've received from the value you think is fair for the business?
spk10: Good morning, Matthew. This is Delisle. A couple of points I think I can make that will further clarify where we are on the paper board and how you'll pulp a process. I really can't get into specifics with respect to what we've seen and how our diligence is going, but there are a couple of other points I can make. When I say criteria, it's other points in addition to valuation differences. And really, the other points of criteria revolve around the suspension of operations at Temisc. I mean, a good example would be the bumping process that is triggered by the reduction of force that is going on at the facility as we speak. Because the union contract gives the more senior employees employment rights versus the junior employees, those senior employees have the right to get a position in paperboard if they so desire. So there's this whole process we need to go through as we go through this mothballing effort. Obviously, when you're changing out personnel, whether it's the hourly and salary personnel, that raises questions or concerns. And so with respect to the potential buyers. So we really need to get through that process and demonstrate when we get to the other end that the plant will be able to run efficiently and effectively going forward. Another issue would be, for example, would be around what's within the perimeter of the sale. There are shared utilities assets that Both of us want to make sure are maintained and operated efficiently and effectively. So, obviously, there's discussions around that of who's going to own them, who's going to operate them, and so forth. So, those discussions are still ongoing as well. In terms of valuations, you know, we point to the sale of the GP Augusta mill as kind of a benchmark. since it's been fairly recent, where it's sold at somewhere in the neighborhood of six to seven times EBITDA and after synergies around five times. And that's kind of been our benchmark with respect to that. And that's where we're working and having discussions with our potential suitors.
spk04: Great. Thanks very much for that, Keller. Maybe next, it sounds like you continue to make good progress on the prebiotic initiative. Can you just maybe update us on how you're thinking about that project today? I think you maybe previously talked about bringing that to market in late 25 or 26. Is that still a relevant timeline? And then if you could just refresh us on any anticipated capital costs and targeted returns to the extent you're able to, please.
spk10: Yeah, so the prebiotics opportunity, It would be located at our JESA facility, taking advantage of some whole product streams that a craft mill generates, and then purifying that stream, and then spray drying and packaging that material to be sold to various animal feed suppliers. We've gotten through what's called the self-grass approval process, grass standing for generally regarded as safe process, and are working closely with a couple of key potential customers as they go through their own independent validation of the benefits of our product versus competitive offerings. And come September, We're going to go through some production trials to make sure that we can produce this at scale before we start committing capital and doing the pre-engineering for the actual prebiotics plant. In terms of timing, we're still targeting late 2025 for a startup. Though that's starting to get a little tight, we still think we can still hit that date. So right now, really haven't hit any speed bumps on that. But as you expect, you have to go through quite a lengthy qualification process, and we're marching through that.
spk04: Thanks very much. And is there anything you're able to say around anticipated capital costs or targeted returns of that project?
spk10: The capital, that's an open question, and that needs to be answered. We do expect that, though, that that capital will be largely financed by green capital. That will be very inexpensive. And in terms of return on equity, it'll meet our thresholds, which is north of 30%.
spk04: Thanks very much. And then last one for me, could you just provide a bit of an update around what you're seeing in the high yield pulp markets and in particular what you're seeing in China?
spk10: Yeah, this is one of my favorite topics, at least something I just talk about with my team all the time about because it's really kind of a moving dynamic. What we're seeing is that the paperboard plants that were recently constructed in China are having trouble finding home for the production of paperboard. So to bring in any kind of cash flow, they're running their pulp lines and then selling those pulp lines to competitive paperboard plants. And that's obviously in competition with the pulp that we bring into China for the same purpose. That dynamic continues, and it's weighing heavily on the pricing in China. So in response to that, we're working to reposition our sales outside of China into other large markets like India and Europe. But in terms of how long this is going to go on, given the questions around consumer activity in China, really don't have an idea right now.
spk02: Okay. Thanks very much for the color. I'll turn it back. Your next question comes from the line of Daniel Harriman with Sidoti.
spk00: Daniel, your line is now open.
spk08: Thank you, Marcus Delisle. Good morning to you both and congrats on the quarter. Just a couple of quick ones from me. First, any concerns at all about the refinancing before the end of the year? And should we think about that as a Q3 event or a Q4 event? And then finally, when we look at your viscose production, it's now down to like 3% of the sales total. So obviously you're managing the commodity volatility there. Is it safe to assume that that's going to continue to be a smaller piece of the revenue pie moving towards the end of the year?
spk10: Hi, Daniel. Good morning. Let me address the issues around the refi first and about where we are with the process. What I can tell you is that, you know, we've been working with Cool Hand Loki now for a couple of months. and have worked with a number of potential lenders as well as look at both the private and public markets and continue to do so. We expect that we'll start receiving proposals for the refi come early September. And so obviously as we go through and evaluate those and pick the lead horses and all that, it's likely that the refi won't get completed until let's say the fourth quarter. So, but again, as we noted in our transcript that we do expect to get this done before year end. With respect to your question
spk02: around, what was it? Viscose, around viscose.
spk10: Yeah, around the viscose. Again, for viscose, similar levels as we've seen through the first half. In 2025 and beyond, we expect to see it decrease further. Let's say in 25 roughly, let's say around 3% lower. And then we're going to continue to put in efforts to continue to push that to zero. And that will largely be accomplished through Ether sales as Ether's demand normalizes back to historical levels.
spk07: Okay, perfect. Delisle, thanks so much. That's very helpful. And best of luck in the balance of the year, guys. Thank you.
spk00: Your next question comes from the line of Dimitri Silverstein with Water Tower Research. Dimitri, your line is now open.
spk09: Good morning, gentlemen, and congratulations on a strong quarter, and good to see you guys swing back into the black. A couple of questions, if I may. First of all, you mentioned that your paperboard business is being impacted by lower prices due to European imports. Can you talk about sort of the dynamic behind that? Why are Europeans becoming more aggressive in terms of importing their product into the U.S.?
spk10: Yeah, and it's, I think, no secret. The issue is just the generally weak economic conditions in Europe. And you could probably say, gee, the weak conditions economic conditions worldwide is really driving it. So you find the European folding box board producers have plenty of capacity looking for any kind of sales. And so we have been seeing imports from Europe actually on an increasing basis here in the first half.
spk09: Okay, so that's something that is going to be a longer-term issue. It's nothing to do with right-sizing inventories or anything like that.
spk10: No, I think that it's all being driven by the weak consumer demand, I would say, in Europe. And until that returns and starts picking up, we'll see that pressure.
spk03: And, Dimitri, that's happened before. It ebbs and flows with, as Dalal mentioned, the general economy in Europe.
spk09: Understood, Mickey. Thank you. And my second question is, you mentioned in your comments stronger ether volumes, probably not to the level that you'd like to see them, but certainly getting better. You also talked about lower input costs, which I'm assuming are wood chips and some other chemicals. Typically, you can interpret these data points as being indicative of perhaps construction demand improving, given that it's a key market for ethers. your wood chip costs are inversely related to the growth in the construction market. So am I reading this right? Are we sort of starting to see an improvement in this important end market for you in Ethers, or am I reading too much into this?
spk10: With respect to Ethers, what I could say there is that there has been some pickup in end market demand in certain areas. But we do believe that some of the increase we saw in Ethers is being driven by value chain doing some restocking. So when you go into Q2, we are discounting the increase we saw in the first half related to restocking. That is one issue. With respect to the input cost, I would say that many of our key inputs, the purchase prices are lower than they were last year. But I also would like to emphasize that we're seeing improvement being driven by the capital investments we made last year. In the plants and so you're seeing an improvement in material usage efficiencies as well In our operations, which would be much more obviously much more long-lasting and finally with respect to the impact on variable costs We're seeing in a getting a benefit from the improved production mix across our facilities It's actually easier for us to make the specialty in many cases than it is to make the commodities. On fixed costs, we've also seen significant improvement. One is obviously productivity is higher this year. You may remember last year we actually throttled back the plants to control inventories. This year the plants are running at capacity. So the unit fixed costs are down this year. And then the other issue is that you may remember around about this time last year, we announced that we were going to aggressively start reducing costs at the facility. And what you're seeing now is you're seeing the comparison and the benefit of that cost reduction in the first half. So the continuation of those costs, those realized cost savings that we began in the second half of 2023. So that's what's going on on the cost side.
spk09: Okay. That's very helpful, Bilal. Thank you for that call. And then one last question on the acetate market. You talked about continuing destocking by customers. Is the expectation still that this is going to wind down by the end of this year, or do you now expect it to get into 2025, given that the global economy certainly isn't getting stronger.
spk10: Yeah, let me make a couple of points about the acetate, the stocking. First, given that Jessup is sold out, we felt that there was a need to levelize the expected demand across the whole year of 2024. Previously, we had said that we would take the stocking hit in the first half and then we start seeing improvements in the second half. After seeing the difficulties we would have on trying to make that happen with the plant being sold out, we worked with our customers and we leveled out that demand for all of 2024. So you're not going to see this huge uptick in 24 because we're essentially now have got essentially a flat line for the whole year. More directly to your question, though, about do we think that it's going to end in 24, that the stocking is going to end in 24? Unfortunately, we continue to see elevated inventories in Asia. And again, I think that's being indicative of the consumer weakness, principally in China, but Asia generally. And so, there is a likelihood that we'll see some of the lower demand bleed off into 25.
spk02: Understood. Thank you. That's been helpful.
spk00: Your next question comes from the line of Sandy Burns with Stifel. Sandy, your line is now open.
spk05: Hi. Good morning, and I'll also add congrats on a strong quarter in this environment. I was wondering if you can comment or maybe break down the different components of the increasing guidance from earlier in the year, you know, versus is it mostly the volume mix improvement and increased confidence in it, more on the cost side, the plan suspension, more clarity on the costs and benefits there? Like, how would you weigh those in terms of how, what drove the increase in guidance?
spk10: Well, part of it is obvious, which is the $10 million in SUSE benefit that we realized in the first half. Obviously, that's 10 million of it, right? And then the second component of that would be call it the advanced sales by some of our customers that wanted to get some inventory in their stock rooms before we suspended operations at Tamiskaming. So we saw some sales move forward a little bit as a result of the suspension at Temiscamingue. And then with respect to ether sales, we did see an uptick in ether sales. And that was related to demand growth or underlying demand growth. And that's driving some of the increase in benefit as well. So if I were to break all that down, I would say that, you know, we're looking at roughly a $15 million or $20 million increase in the guidance. We look at the midpoints. Ten of that was sues, and I would say roughly five and five on Ethers, the Ethers. improvement in ether's demand, and then a $5 million improvement in the move forward on sales related to the temiscaming suspension.
spk05: Okay, great.
spk02: That's helpful. Thank you.
spk00: Again, in order to ask a question, press star, then the number one on your telephone keypad. Hit star, followed by the number one on your telephone keypad. Your next question comes from the line of... So there's no further question at this time. I will now turn the call over to Delau for closing remarks.
spk10: All right. Well, thank you once again for joining our call today. Certainly appreciate your interest and support in the company. I'm very proud of the hard work and dedication that has been shown by the RIAM team and are very confident in our ability to continue to enhance our profitability and reduce our debt and leverage. I look forward to providing further updates on all our ongoing project initiatives and value your contribution and support as we strive for the long-term success and growth of the company. We are committed to maintaining transparency and open communication, so please feel free to contact us if you have any questions or need further information. So thank you again for your participation.
Disclaimer